Table 3: Changes in Parameters of the SF-36 Questionnaire: 28 Weeks Compared to the Placebo Phase by Specified Medication at the End of the Study. General Linear Method, Measurements at 0, 6,12,18 and 24 Weeks. Statistically Significant Changes are Bolded

Comparison Physical Functioning Role- Physical Bodily Pain General Health Total Physical Health Vitality Social Functioning Role- Emotional Mental Health Total Mental Health Total SF-36
Candesartan 8/16 mg vs placebo change n=24 -7.8 -9.4 -5.7 -7.0 -5.9 -5.4 0 -8.4 -0.2 -4.4 -5.7
SD 16.4 36.0 27.4 26.9 16.4 22.4 19.2 28.2 13.7 13.9 15.4
p-value 0.002 0.525 0.509 0.197 0.055 0.125 0.708 0.246 0.048 0.063 0.034
CA* + HCTZ** vs placebo change n=23 +3.4 0 -2.4 -0.4 -2.6 -5.4 -4.9 -2.9 -1.0 -2.9 +0.5
SD 28.1 45.9 35.3 22.7 24.2 28.5 28.6 21.9 21.9 24.3 31.6
p-value 0.044 0.663 0.974 0.569 0.636 0.145 0.786 0.925 0.619 0.761 0.888
CA* + HCTZ** + felodipine 5 mg vs placebo change n=18 -0.9 +4.4 +4.7 -1.6 +1.7 -2.9 +0.7 +13.7 +1.6 +3.7 +3.2
SD 28.5 55.3 34.7 32.6 31.9 30.8 32.3 51.4 26.5 31.5 32.2
p-value 0.106 0.308 0.354 0.654 0.146 0.111 0.122 0.026 0.044 0.115 0.042

CA*= 8/16 mg of candesartan, HCTZ**=hydrochlorothiazide 12.5/25 mg.